New Treatments of Hepatorenal Syndrome

ABSTRACT

Hepatorenal syndrome (HRS) is a common complication of advanced cirrhosis, characterized by renal failure and major abnormalities in the systemic circulatory function. Renal failure is caused by intense vasoconstriction of the renal circulation. The syndrome is probably the final consequence of an extreme underfilling of the arterial circulation, secondary to vasodilatation in the splanchninc vascular bed and a decrease in cardiac output due to central hypovolemia. The diagnosis of HRS is based on the exclusion of other causes of renal failure. The survival of patients with HRS is very short, particularly when there is rapidly progressive renal failure (type-1 HRS). Liver transplantation is the best therapeutic option but its applicability is low. During the past few years effective treatment for HRS, such as vasoconstrictor drugs (vasopressin analogues, ∝-adrenergic agonists) associated with intravenous albumin infusion and transjugular intrahepatic portosystemic shunts (TIPS), have been introduced. They improve circulatory function, normalize serum creatinine, and may improve survival. Sequential treatment with vasoconstrictors plus albumin and TIPS is an attractive therapeutic possibility. Plasma volume expansion with albumin at infection diagnosis in patients with spontaneous bacterial peritonitis and the administration of pentoxiphilline in patients with severe alcoholic hepatitis significantly reduce the development of type-1 HRS.

KEYWORDS

Renal failure - cirrhosis - portal hypertension - circulatory dysfunction

REFERENCES

• 1 Ginès P, Rodés J. Clinical disorders of renal function in cirrhosis with ascites. In: Arroyo V, Ginès P, Rodés J, Schrier RW Ascites and Renal Dysfunction in Liver Disease: Pathogenesis, Diagnosis, and Treatment. Malden, MA; Blackwell Science 1999: 36-62
• 2 Hecker R, Sherlock S. Electrolyte and circulatory changes in terminal liver failure.  Lancet. 1956;  271 1121-1125
• 3 Ginès A, Escorsell A, Ginès P et al.. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites.  Gastroenterology. 1993;  105 229-236
• 4 Arroyo V, Ginès P, Gerbes A et al.. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis.  Hepatology. 1996;  23 164-176
• 5 Cabrera J, Arroyo V, Ballesta A M et al.. Aminoglycoside nephrotoxicity in cirrhosis: value of urinary beta 2-microglobulin to discriminate functional renal failure from acute tubular damage.  Gastroenterology. 1982;  82 97-105
• 6 Dudley F J, Kanel G C, Wood L J, Reynolds T B. Hepatorenal syndrome without avid sodium retention.  Hepatology. 1986;  6 248-251
• 7 Hampel H, Bynum G D, Zamora E, El-Serag H B. Risk factors for the development of renal dysfunction in hospitalized patients with cirrhosis.  Am J Gastroenterol. 2001;  96 2206-2210
• 8 Brater D C, Anderson S A, Brown-Cartwright D, Toto R D. Effects of nonsteroidal antiinflammatory drugs on renal function in patients with renal insufficiency and in cirrhotics.  Am J Kidney Dis. 1986;  8 351-355
• 9 Westphal J F, Brogard J M. Drug administration in chronic liver disease.  Drug Saf. 1997;  17 47-73
• 10 Toledo C, Salmerón J M, Rimola A et al.. Spontaneous bacterial peritonitis in cirrhosis: predictive factors of infection resolution and survival in patients treated with cefotaxime.  Hepatology. 1993;  17 251-257
• 11 Follo A, Llovet J M, Navasa M et al.. Renal impairment following spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis.  Hepatology. 1994;  20 1495-1501
• 12 Navasa M, Follo A, Filella X et al.. Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality.  Hepatology. 1998;  27 1227-1232
• 13 Rodés J, Arroyo V, Bosch J. Clinical types and drug therapy of renal impairment in cirrhosis.  Postgrad Med J. 1975;  51 492-497
• 14 Goyal R K, Irano I. The enteric nervous system.  N Engl J Med. 1996;  334 1106-1115
• 15 Gupta S, Morgan T R, Gordan G S. Calcitonin-gene related peptide in hepatorenal syndrome.  J Clin Gastroenterol. 1992;  14 122-126
• 16 Bendtsen F, Schifter S, Henriksen J H. Increased circulation calcitonin-gene related peptide (CGRP) in cirrhosis.  J Hepatol. 1991;  12 118-123
• 17 McNicol P L, Liu G, Shulkes A, Hardy K J, Jones R M. Vasoactive intestinal peptide and calcitonin-gene related peptide and hemodynamics during human liver transplantation.  Transplant Proc. 1993;  25 1830-1831
• 18 Moller S, Bendtsen F, Schifter S, Henriksen J H. Relation of calcitonin gene-related peptide to systemic vasodilation and central hypovolaemia in cirrhosis.  Scand J Gastroenterol. 1996;  31 928-933
• 19 Hori N, Okanoue T, Sawa Y, Kashima K. Role of calcitonin gene-related peptide in the vascular system on the development of the hyperdynamic circulation in conscious cirrhotic rats.  J Hepatol. 1997;  26 1111-1119
• 20 Benoit J N, Granger D N. Splanchnic hemodynamics in chronic portal hypertension.  Semin Liver Dis. 1986;  6 287-298
• 21 Vorobioff J, Bredfeldt J E, Groszmann R J. Increased blood flow through the portal system in cirrhotic rats.  Gastroenterology. 1984;  87 1120-1126
• 22 Vorobioff J, Bredfeldt J E, Groszmann R J. Hyperdynamic circulation in portal hypertensive rat model: a primary factor for maintenance of chronic portal hypertension.  Am J Physiol. 1983;  244 G52-G57
• 23 Schrier R W, Arroyo V, Bernardi M, Epstein M, Henriksen J H, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis.  Hepatology. 1988;  8 1151-1157
• 24 Lee F Y, Albillos A, Colombato L A, Groszmann R J. The role of nitric oxide in the vascular hyporesponsiveness to methoxamine in portal hypertensive rats.  Hepatology. 1992;  16 1043-1048
• 25 Sieber C, López-Talavera J C, Groszmann R J. Role of nitric oxide in the in vitro splanchnic vascular hyporeactivity in ascitic cirrhotic rats.  Gastroenterology. 1993;  104 1750-1754
• 26 Maroto A, Gines A, Salo J et al.. Diagnosis of functional renal failure of cirrhosis by Doppler sonography: prognostic value of resistive index.  Hepatology. 1994;  20 839-844
• 27 Fernández-Seara J, Prieto J, Quiroga J et al.. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure.  Gastroenterology. 1989;  97 1304-1312
• 28 Maroto A, Gines P, Arroyo V et al.. Brachial and femoral artery blood flow in cirrhosis: relationship to kidney dysfunction.  Hepatology. 1993;  17 788-793
• 29 Guevara M, Bru C, Ginés P et al.. Increased cerebral vascular resistance in cirrhotic patients with ascites.  Hepatology. 1998;  28 39-44
• 30 Tristani F E, Cohn J H. Systemic and renal hemodynamics in oliguric hepatic failure: effect of volume expansion.  J Clin Invest. 1967;  46 1894-1906
• 31 Lebrec D, Kotelansku B, Cohn J H. Splanchnic hemodynamic factors in cirrhosis with refractory ascites.  J Lab Clin Med. 1979;  93 301-309
• 32 Ruiz-del-Arbol L, Urman J, Fernandez J et al.. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis.  Hepatology. 2003;  38 1210-1218
• 33 Ruiz-del-Arbol L, Monescillo A, Arocena C et al.. Circulatory function and hepatorenal syndrome in cirrhosis.  Hepatology. 2005;  42 439-447
• 34 Schroeder E T, Eich R H, Smulyan H, Gould A B, Gabuzda G J. Plasma renin levels in hepatic cirrhosis: relationship to functional renal failure.  Am J Med. 1970;  49 186-191
• 35 DiBona G F. Renal nerve activity in hepatorenal syndrome.  Kidney Int. 1984;  25 841-853
• 36 Henriksen J H, Ring-Larsen H. Hepatorenal disorders: role of the sympathetic nervous system.  Semin Liver Dis. 1994;  14 35-43
• 37 Dudley F J, Esler M D. The sympathetic nervous system in cirrhosis. In: Arroyo V Ascites and Renal Dysfunction in Liver Disease. Malden, MA; Blackwell Science 1999: 198-219
• 38 Arroyo V, Planas R, Gaya J et al.. Sympathetic nervous activity, renin-angiotensin system and renal excretion of prostaglandin E2 in cirrhosis: relationship to functional renal failure and sodium and water excretion.  Eur J Clin Invest. 1983;  13 271-278
• 39 Rimola A, Gines P, Arroyo V et al.. Urinary excretion of 6-keto-prostaglandin F1-alpha, thromboxane B2 and prostaglandin E2 in cirrhosis with ascites: relationship to functional renal failure (hepatorenal syndrome).  J Hepatol. 1986;  3 111-117
• 40 Moore K P. Arachidonic acid metabolites and the kidney in cirrhosis. In: Arroyo V Ascites and Renal Dysfunction in Liver Disease. Malden, MA; Blackwell Science 1999: 249-272
• 41 Arroyo V. Diuretic-resistant ascites in cirrhosis: mechanism and treatment.  Acta Gastroenterol Belg. 1990;  53 249-255
• 42 Ma Z, Lee S S. Cirrhotic cardiomyopathy: getting to the heart of the matter.  Hepatology. 1996;  24 451-459
• 43 Sort P, Navasa M, Arroyo V et al.. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis.  N Engl J Med. 1999;  341 403-409
• 44 Iwakiri Y, Groszmann R J. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule.  Hepatology. 2006;  43(suppl 1) S121-S131
• 45 Harry R, Auzinger G, Wendon J. The clinical importance of adrenal insufficiency in acute hepatic dysfunction.  Hepatology. 2002;  36 395-402
• 46 Tsai M H, Peng Y S, Chen Y C et al.. Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock.  Hepatology. 2006;  43 673-681
• 47 Gonwa T A, Morris C A, Goldstein R M, Husberg B S, Klintmalm G B. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome: experience in 300 patients.  Transplantation. 1991;  51 428-430
• 48 Lerut J, Goffette P, Laterre P F, Donataccio M, Reynaert M S, Otte J B. Sequential treatment of hepatorenal syndrome and posthepatic cirrhosis by intrahepatic portosystemic shunt (TIPS) and liver transplantation.  Hepatogastroenterology. 1995;  42 985-987
• 49 Gonwa T A, Klintmalm G B, Jennings L S, Goldstein R M, Husberg B. Impact of pretransplant renal function on survival after liver transplantation.  Transplantation. 1995;  59 361-365
• 50 Seu P, Wilkinson A H, Shaked A, Busuttil R W. The hepatorenal syndrome in liver transplant recipients.  Am Surg. 1991;  57 806-809
• 51 Rimola A, Gavaler J S, Schade R R, el-Lankany S, Starzl T E, Van Thiel D H. Effects of renal impairment on liver transplantation.  Gastroenterology. 1987;  93 148-156
• 52 Guevara M, Ginès P, Fernández-Esparrach G et al.. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion.  Hepatology. 1998;  27 35-41
• 53 Gulberg V, Bilzer M, Gerbes A L. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine.  Hepatology. 1999;  30 870-875
• 54 Angeli P, Volpin R, Gerunda G et al.. Reversal of type 1 HRS with the administration of midodrine and octreotide.  Hepatology. 1999;  29 1690-1697
• 55 Uriz J, Ginés P, Cardenas A et al.. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome.  J Hepatol. 2000;  33 43-48
• 56 Mulkay J P, Louis H, Donckter V et al.. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study.  Acta Gastroenterol Belg. 2001;  64 15-19
• 57 Colle I, Durand F, Pessione F et al.. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with terlipressin: a retrospective analysis.  J Gastroenterol Hepatol. 2002;  17 882-888
• 58 Halimi C, Bonnard P, Bernard B et al.. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study.  Eur J Gastroenterol Hepatol. 2002;  14 153-158
• 59 Ortega R, Ginés P, Uriz J et al.. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, non-randomized study.  Hepatology. 2002;  36 941-948
• 60 Duvoux C, Zanditenas D, Hezode C et al.. Effects of noradrenaline and albumin in patients with type 1 hepatorenal syndrome: a pilot study.  Hepatology. 2002;  36 374-380
• 61 Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin S K. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial.  J Gastroenterol Hepatol. 2003;  18 152-156
• 62 Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.  Hepatology. 2004;  40 55-64
• 63 Linas S L, Schaefer J W, Moore E E, Good Jr J T, Giansiracusa R. Peritoneovenous shunt in the management of the hepatorenal syndrome.  Kidney Int. 1986;  30 736-740
• 64 Pomier-Layrargues G, Paquin S C, Hassoun Z, Lafortune M, Tran A. Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study.  Hepatology. 2003;  38 238-243
• 65 Moreau R, Durand F, Poynard T et al.. Terlipressin in patients with cirrhosis and type y HRS: a retrospective multicenter study.  Gastroenterology. 2002;  122 923-930
• 66 Fernandez J, Navasa M, Garcia-Pagan J C et al.. Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis.  J Hepatol. 2004;  41 384-390
• 67 Fernandez J, Monteagudo J, Bargallo X et al.. A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis.  Hepatology. 2005;  42 627-634
• 68 Brensing K A, Textro J, Perz J et al.. Long-term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant patients with hepatorenal syndrome: a phase II study.  Gut. 2000;  47 288-295
• 69 Guevara M, Ginés P, Bandi J C et al.. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems.  Hepatology. 1998;  28 416-422
• 70 Mitzner S R, Stange J, Klammt S et al.. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial.  Liver Transpl. 2000;  6 277-286
• 71 Catalina M V, Barrio J, Anaya F et al.. Hepatic and systemic haemodynamic changes after MARS in patients with acute on chronic liver failure.  Liver Int. 2003;  23(suppl 3) 39-43
• 72 Jalan R, Sen S, Steiner C, Kapoor D, Alisa A, Williams R. Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis.  J Hepatol. 2003;  38 24-31
• 73 Stange J, Hassanein T, Lynch P et al.. Short-term survival of patients with severe intractable hepatic encephalopathy: the role of albumin dialysis.  Hepatology. 2005;  42(suppl 1) 286A
• 74 Alessandria C, Venon W D, Marzano A, Barletti C, Fadda M, Rizzetto M. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2.  Eur J Gastroenterol Hepatol. 2002;  14 1363-1368
• 75 Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial.  Gastroenterology. 2000;  119 1637-1648